Corzyna Will Be a New Med for Chronic Chest Pain

June 2021

Corzyna (ranolazine) will be a new option for patients with chronic chest pain, or angina.

It's already been used in the U.S. for over a decade under the brand name Ranexa.

Corzyna will be the first angina med that doesn't affect heart rate or blood pressure.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Encourage COVID-19 Vaccination for Adolescents
COVID-19 Help Increase COVID-19 Vaccine Acceptance
Angina Corzyna Will Be a New Med for Chronic Chest Pain
Opioids Get Prepared to Handle Tramadol as a Controlled Substance
Rosacea Sort Through Topical Meds for Rosacea
Communication Be Ready to Help People Who Are Deaf or Hard of Hearing
Topicals Keep Patients Getting Topical Steroids Safe
Psychiatry Be Alert for PTSD Linked to the COVID-19 Pandemic
Multiple Sclerosis Stay Informed About New Multiple Sclerosis Meds